Visit us at EBCC 2026

This year at EBCC, Exact Sciences will host a symposium featuring a multidisciplinary expert panel and welcoming attendees at Booth 22, as we mark an important milestone – more than 2 million patients tested worldwide with the Oncotype DX Breast Recurrence Score® test.

Satellite Symposium

Join the Exact Sciences Satellite Symposium on March 26 at 12:45-13:45 CEST, in Room 112.

Deciding Together: How Multigene Assays support Shared Decision Making in Early Breast Cancer

Hear from experts Mafalda Oliveira, Henry Cain, Maria Vittoria Dieci, and Stephanie Christodoulidou as they explore how multigene assays support shared decision making in early-stage breast cancer. Gain practical insights on integrating genomic information into clinical practice to support more informed and confident treatment decisions.
Thumbnail of the Exact Sciences EBCC 2026 symposium flyer.

Agenda

12:45 – 12:50
Welcome and Introduction
Mafalda Oliveira

12:50 – 13:05
Confidence and Consent: How PROs Strengthen Shared Decision Making
Henry Cain

13:05 – 13:20
From Report to Treatment Decision: Translating Multigene Results into Clinical Practice
Maria Vittoria Dieci

13:20 – 13:30
Shared Decision Making: Deciding Together in Practice
Stephanie Christodoulidoui

13:30 – 13:45
Panel Discussion
Mafalda Oliveira, Henry Cain, Maria Vittoria Dieci, Stephanie Christodoulidou

Visit us at Booth 22

More than 2 million patients worldwide have now benefited from the Oncotype DX Breast Recurrence Score® test, a milestone that reflects our ongoing commitment to supporting confident, individualised treatment in early-stage breast cancer.

Join us at Booth 22 to learn more about the Oncotype DX® test and how it can be used to help support treatment decision-making for patients with early-stage HR+/ HER2- breast cancer.

We look forward to seeing you there.

Doctor sitting with patient having a discussion.
Get in touch
Have questions about Oncotype DX?